Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsStephen D. Griffin is recorded as Board Member at Anika Therapeutics, Inc. (ANIK) since January 1, 2026 and CFO and CEO at Anika Therapeutics, Inc. (ANIK). The newest filing on record that lists Stephen D. Griffin as CEO and Board Member at Anika Therapeutics, Inc. (ANIK) is dated April 28, 2026. The newest filing on record that lists Stephen D. Griffin as CFO at Anika Therapeutics, Inc. (ANIK) is dated April 28, 2025. Anika Therapeutics, Inc. reported in an 8-K filed June 23, 2026 that Stephen D. Griffin was appointed Class III director, effective June 18, 2026. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $2,033,370 for Stephen D. Griffin in fiscal 2025, including a base salary of $500,000. Disclosed compensation is on record for 2 fiscal years. Stephen D. Griffin has spoken on 3 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on February 26, 2026. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Steve Griffin (CEO and Board Member) and 7 others.
“As a result of this vote, Mr. Fischetti, Mr. Henneman and Mr. Griffin were elected as Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal.”
“Before turning to the results, I want to express how grateful I am for the opportunity to lead Anika and for the continued trust and support of our Board as I step into the CEO role.”
“Our third quarter results reflect steady progress across key areas in both profit and cash flow, with performance in line with expectations and signs of continued momentum.”
“Before we dive into the financial results, I want to begin with an update on the production challenges we encountered earlier this quarter. Since April, our teams have successfully resolved the lower production yields and restored output to historic levels.”
2026-01-01–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2025
Start not stated–present
Last confirmed April 28, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO, CEO, Board Member
2026-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | $500,000 | $2,033,370 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $278,846 | $2,646,150 |
